August 20th, 2013 Pill Reminder App now free on Apple app store

The popular and easy-to-use Pill Reminder app for iPhone or iPod touch is now free to everyone.

Use this application to manage any combination of medications, vitamins/supplements and birth control pills.

The intuitive interface lets you build a list of medications and setup reminders with ease in just a few seconds using the built-in database of drugs. Set up any type of recurring reminders using the flexible scheduling options to let you know when to take your meds and when to get your prescription refills. Other features include the ability to add a photo, select dosage information, write notes, snooze reminders, keep a calendar history and much more. The app also provides easy access to comprehensive medical information for your drugs including: side effects, dosage, interactions, pregnancy safety and more.

Download the App here…

This app is intended for educational purposes only. You must not rely on this application alone to remember to take your prescriptions or to replace medical advice, diagnosis or treatment. Always consult with your health-care professional.

August 8th, 2013

Q2 2013 Drug Sales Data Released: Humira Climbs and Posts Double-Digit Growth

The latest U.S. drug sales data has been released by Since Q2 2012, Otuska’s antipsychotic Abilify and AstraZeneca’s acid reducer Nexium have held either the number one or two spot in top dollar sales. This quarter, both agents continue to maintain their stronghold; each post close to $1.5 billion in sales. Humira, AbbVie’s key tumor necrosis factor (TNF) blocker, climbs three notches and sees a double-digit gain for the quarter. Biogen Idec’s Avonex Pen and Avonex take a double hit this quarter and lose $187 million in sales.

View the data here…

May 5th, 2013

Q1 2013 Drug Sales Data Released: Rough U.S Flu Season Boosts Numbers for Tamiflu

The latest U.S. drug sales data has been released by The top five drugs have minor shifts in rank but exhibit positive growth for Q1 2013. Abilify, Otsuka’s second generation antipsychotic, and Nexium, AstraZeneca’s leading acid blocker, rank as the top two drugs by sales for the fourth quarter in a row. Both agents hover in the $1.5 billion range for quarterly sales. In addition, the Tamiflu statistics show that the most recent U.S. flu season hit long and hard.

View the data here…

April 9th, 2013 Receives Fourth Webby Nomination!

We are extremely proud to announce that has been nominated for the prestigious Webby Awards. Kudos to the hard working team! This is their fourth nomination in five years. To yet again be judged among the Internet’s top 5 health web sites is indeed an honor.

But wait, there’s more… we need your vote! The Webby People’s Voice Awards is also one of the few major awards that invite the public to participate by allowing you to vote for your favorite nominee. If you found helpful, we’d really appreciate your vote.

Update: Voting closed.

Thanks for your support!
The Team


March 7th, 2013 Launches New iOS and Android Medication Guide

Today we are officially launching a new consumer tool to join other leading apps – the Medication Guide. Patients and caregivers will have instant access to their most recent personal medication records, the latest advice on drug therapy and medical conditions, and breaking health news tailored to their needs. In addition, consumers can easily navigate through the most trusted and unbiased sources of medical information to make informed health decisions on-the-go.

The Medication Guide is now available as a free download on iOS and Android mobile platforms.

Download here…

February 7th, 2013

Q4 2012 Drug Sales Data Released: Abilify Overtakes Nexium as the Top Drug by Sales

The latest U.S. drug sales data have been released by At the close of 2012, Otsuka’s antipsychotic Abilify overtakes AstraZeneca’s acid reducer Nexium and moves into the number one spot with over $1.47 billion in quarterly sales. Sales expanded for all five front-runners over the quarter, although none reached double-digit growth. There are no changes in the top selling pharmaceutical classes, which include antipsychotics, proton pump inhibitors, and statins.

View the data here…

View the press release here…

January 28th, 2013 Pill Reminder featured on Fox Television Orlando

Our popular Pill Reminder app was featured on WOFL Fox 35 Orlando recently. Here’s what they had to say…

“People need to take a medicine to keep that blood pressure down and it’s hard to motivate them,” said Dr. Timothy Hendrix of Centra Care. “It’s hard to remind them to take that everyday if they’re not having symptoms with it.”

But like everything else, there’s an app for that. Pill Reminder, an app offered through the website, costs .99 cents and allows you to list all your prescriptions medications and vitamins, and set alarms to remind you when to take them. It will also keep a personal record of how many times you’ve missed doses.

Download the Pill Reminder App for iOS

December 18th, 2012

Transparency in Clinical Trials: A New Paradigm Shift?

The British Medical Journal (BMJ), a leading, peer-reviewed medical journal, has announced that beginning in January 2013 it will require all authors of drug or device clinical trials who publish in BMJ – whether industry-funded or not – to provide detailed scientific study data to anyone with a reasonable request. Although the policy specifics are still under discussion, it is expected trial data down to the anonymised patient level would be required. In addition, BMJ will publicize instances in which requests for data were rejected by authors.

Read the entire article here…


November 21st, 2012

Q3 2012 Drug Sales Data Released: Nexium and Abilify Remain the Leading Brands

The latest U.S. drug sales data has been released by As in the previous quarter, proton-pump inhibitors, antipsychotics and statins remain in the top-selling therapeutic categories. Merck’s asthma and allergy preventive Singulair predictably drops out of the top five drugs due to Q3 patent loss. AstraZeneca’s Nexium, not forecast to lose patent protection until May 2014, once again holds the top spot with over $1.42 billion in sales.

View the data here…

View the press release here…


August 29th, 2012

Bristol-Myers Squibb Acquisition Results in $1.8 Billion Loss

Bristol-Myers Squibb (BMS) has announced that they will discontinue all development of their chronic hepatitis C (HCV) treatment BMS-986094, a nucleotide polymerase (NS5B) inhibitor previously in Phase 2 clinical trials. BMS reports that nine study patients were hospitalized with heart and kidney toxicity, with one patient death due to heart failure. The exact cause of these adverse events are not yet known.

BMS states halting development of BMS-986094 has been governed by their strong commitment to patient safety. They have agreed to further investigate the toxicity profile of BMS-986094, and in cooperation with the U.S. Food and Drug Administration, share safety data with other companies involved in the development of investigational HCV compounds.

Earlier this year BMS acquired the pharmaceutical company Inhibitex Inc. for $2.5 billion, and along with that procurement came the then promising BMS-986094. BMS has now announced that they will take a $1.8 billion charge related to the collapse of the HCV treatment which will be evident in Q3 2012 results.

A failed investigational agent is not the only challenge for BMS. The expected patent loss of Plavix (clopidogrel) in May resulted in an initial 42% drop in Plavix sales in Q2 2012, and further drops are likely.

But not all news is bad: In a joint venture with AstraZeneca, BMS recently won a bid to acquire Amylin Pharmaceuticals for over $7 billion in an effort to bolster their diabetes market, a therapeutic area projected to grow rapidly in coming years. Amylin has a strong diabetes presence with Byetta and Bydureon already on the market and others in the pipeline. This acquisition was considered by some analysts to be a major coup for both BMS and AstraZeneca. Bydureon, an injectable GLP-1 agonist, pairs well with the AstraZeneca-BMS portfolio of Onglyza and investigational agent dapagliflozin.

Joint venture pharma deals are one way to recover from revenue loss due to blockbuster-to-generic switches. Other companies that have entered into agreements this summer include Johnson & Johnson and Pfizer. While the risks are substantial as proven by the BMS $1.8 billion dollar loss, gaining royalties from mid- to late stage products can often prove profitable.